|
 |
|
POSTER PRESENTATIONS
SESSION III |
|
ASTHMA/ALLERGY
|
|
Cost Studies |
|
PAA1
|
CLINICAL
EFFECTIVENESS
OF
ADJUSTABLE
DOSING
SINGLE
INHALER
BUDESONIDE/FORMOTEROL
FOR
ASTHMA
AND
BUDGET
IMPACT
ANALYSIS
|
|
|
Kaczor
M, Becla
L,
Wojcik
R,
Dardzinski
W,
Walczak
J,
Nogas G |
|
|
Arcana
Institute,
Cracow,
Poland
|
|
PAA2
|
EFFECT
OF
SUBLINGUAL
IMMUNOTHERAPY
(SLIT)
ON
DIRECT
MEDICAL
COSTS
FOR
PATIENTS
WITH
ALLERGIC
RHINITIS
AND
ASTHMA:
RESULTS
FROM THE
SIMAP
DATABASE
STUDY
|
|
|
Berto P1, Bassi M2, Cadario G3, Cantarutti L4,
Contiguglia
R5,
Crivellaro
M6,
Di
Gioacchino
M7,
Frati F8,
Magazzù
C5,
Marengo
F3,
Scamarcia
A4,
Schiappoli
M6,
Valle C9,
Verna N7,
Giaquinto
C10 |
|
|
1Pbe
consulting,
Verona,
Italy,
2Rho
Hospital,
Cerchiate
di Pero
(MI),
Italy,
3Azienda
Ospedaliera
S.Giovanni
Battista
di
Torino
(Molinette),
Torino,
Italy,
4SOSEPE,
Padova,
Italy,
5AUSL
5,
Messina,
Italy,
6Azienda
Ospedaliera
Verona,
Verona,
Italy,
7D'Annunzio
University,
Chieti,
Italy,
8Stallergenes
Italy,
Milano,
Italy,
9Ospedale
San
Paolo,
Milano,
Italy,
10University
of
Padova,
Padova,
Veneto,
Italy
|
|
PAA3
|
COST OF
MANAGING
ASTHMA
EXACERBATIONS
WITH
STABLE
DOSING
OF
SALMETEROL/FLUTICASONE
COMBINED
PRODUCT
(SFC)
COMPARED
WITH
ADJUSTABLE
MAINTENANCE
DOSING
(AMD) OF
FORMOTEROL/
BUDESONIDE
COMBINED
PRODUCT
(FBC) IN
POLAND
|
|
|
Orlewska
E1,
Cel M2,
Glogowski
C2 |
|
|
1Centrum
Farmakoekonomiki,
Warsaw,
Poland,
2GSK
Commercial
Sp. z
o.o,
Warsaw,
Poland
|
|
PAA4
|
PHARMACOECONOMIC
ANALYSIS
OF USE
OF A
SIMBICORT
TURBUHALER
AND
SERETIDE
MULTIDISK
OF
ASTHMA
PATIENTS
|
|
|
Kulikov
A,
Lomakin
A,
Krysanov
I,
Polivanov
V |
|
|
Moscow Medical Academy, Moscow, Russia |
|
PAA5
|
ECONOMIC
EVALUATION
OF A NEW
AIRWAY
INFLAMMATION
MONITOR
IN THE
DIAGNOSIS
AND
MANAGEMENT
OF
ASTHMA
IN
GERMANY
|
|
|
Berg J1, Lindgren P1, Jönsson B2 |
|
|
1Stockholm
Health
Economics,
Stockholm,
Sweden,
2Stockholm
School
of
Economics,
Stockholm,
Sweden
|
|
PAA6
|
VALUING
REDUCED
RATES OF
OROPHARYNGEAL
ADVERSE
EVENTS:
COMPARISON
OF
CICLESONIDE
WITH
FLUTICASONE
PROPIONATE
|
|
|
Wlodarczyk
JH1,
Harvey C2,
Caeser M3 |
|
|
1John
Wlodarczyk
Consulting
Services,
New
Lambton,
NSW,
Australia,
2Altana
Pharma
Pty Ltd,
NOrth
Ryde,
NSW,
Australia,
3ALTANA
Pharma
AG,
Konstanz,
Germany
|
|
PAA7
|
ANALYZING
THE
INFLUENCE
OF
SWITCHING
BETWEEN
DIFFERENT
ASTHMA
REGIMES
ON
MEDICATION
ADHERENCE
TO
ASTHMA
THERAPY,
RESOURCE
UTILIZATION
AND
COSTS
|
|
|
Buesch K1, Welte R2, Singer C2 |
|
|
1GSF-National
Research
Center
for
Environment
and
Health,
Neuherberg,
Bavaria,
Germany,
2GlaxoSmithKline,
Munich,
Germany
|
|
PAA8
|
A
COMPARISON
OF
CLAIMS
RATIO
BETWEEN
PRIMARY
AND
SECONDARY
DRUGS IN
THE
MANAGEMENT
OF
ASTHMA.
A
CANADIAN
ANALYSIS
|
|
|
Ciobanu
A |
|
|
AstraZeneca,
Mississauga,
ON,
Canada
|
|
 |
|
Health
Care Use
& Policy
Studies |
|
PAA9
|
THE
EFFECTS
OF
GENERIC-ONLY
DRUG
COVERAGE
ON
INHALED
CORTICOSTEROID
EXPENDITURES
AND USE
|
|
|
Fung V1, Fireman B1, Brand R2, Newhouse JP3,
Hsu J1 |
|
|
1Kaiser
Permanete,
Oakland,
CA, USA,
2University
of
California
at San
Francisco,
San
Francisco,
CA, USA,
3Harvard
University,
Boston,
MA, USA
|
|
PAA10
|
HEALTH
PLAN
STRUCTURE
AND
EXPENDITURES
FOR
ASTHMA
CARE
|
|
|
Nurmagambetov
T,
Atherly
A,
Williams
S, Redd
S |
|
|
Centers
for
Disease
Control
and
Prevention,
Atlanta,
GA, USA
|
|
Methods
&
Concepts |
|
PAA11
|
COST-EFFECTIVENESS
ANALYSIS
FOR THE
ASSESSMENT
OF
PREVENTIVE
SCHEMES
BASED ON
GENETIC
SCREENING
|
|
|
Gutierrez
de Mesa
E1,
Hidalgo
I1,
Christidis
P1,
Ciscar
JC1,
Vegas E2,
Ibarreta
D1 |
|
|
1Institute
for
Prospective
Technological
Studies,
JRC-European
Commission,
seville,
Spain,
Spain,
2Servicio
Madrleño
de
Salud,
Alcala
de
Henares.
MADRID,
Spain
|
|
Patient
Reported
Outcomes |
|
PAA12
|
THE
EFFECT
OF
SWITCHING
ON
ADHERENCE
TO
DIFFERENT
TYPES OF
ASTHMA
TREATMENT
|
|
|
Buesch K1, Singer C2, Welte R2 |
|
|
1GSF-National
Research
Center
for
Environment
and
Health,
Neuherberg,
Bavaria,
Germany,
2GlaxoSmithKline,
Munich,
Germany
|
|
PAA13
|
OBTAINING
POPULATION
REFERENCE
VALUES
FOR THE
ESPRINT-15
QUESTIONNAIRE,
A
SPECIFIC
QUALITY
OF LIFE
SCALE
FOR
ALLERGIC
RHINITIS
(AR)
|
|
|
Valero A1,
Monclús
L2,
Baro E3,
on
behalf
of
Esprint
Study
Investigators
-4 |
|
|
1Hospital
Clínic i
Provincial
de
Barcelona,
Barcelona,
Spain,
2J.
Uriach &
Cia,
S.A,
Palau-solità
i
plegamans,
Barcelona,
Spain,
33D
Health
Research,
Barcelona,
Spain,
4Esprint
Study
Investigators,
Spain,
Spain
|
|
PAA14
|
PATIENT-PERCEIVED
SIDE
EFFECTS
OF
CICLESONIDE
AS
COMPARED
TO
FLUTICASONE
PROPIONATE
IN THE
TREATMENT
OF
MODERATE
ASTHMA
USING
THE
INHALED
CORTICOSTEROID
QUESTIONNAIRE
|
|
|
van der
Molen T1,
Leichtl
S2,
Caeser M2 |
|
|
1University
of
Groningen,
Groningen,
The
Netherlands,
2ALTANA
Pharma
AG,
Konstanz,
Germany
|
|
PAA15
|
THE
CONSTRUCT
VALIDITY
AND
TEST-RETEST
RELIABILITY
OF THE
INHALED
CORTICOSTEROID
QUESTIONNAIRE
(ICQ): A
PATIENT
SELF-REPORTED
SIDE
EFFECT
SCALE
|
|
|
Foster
JM1, Van Sonderen E1, Lee AJ2, Sanderman
R1,
Van der
Molen T1 |
|
|
1University
of
Groningen,
Groningen,
The
Netherlands,
2University
of
Aberdeen,
Aberdeen,
UK
|
|
 |
|
CARDIOVASCULAR
|
|
Clinical
Outcomes
Studies |
|
PCV1
|
CLINICAL
IMPACT
OF
DIAGNOSTIC
IMAGING
OF LOWER
EXTREMITY
PERIPHERAL
VASCULAR
DISEASE
|
|
|
Scranton
R1,
Dhingra
R1,
Lawler E2,
Hay JW3,
Yucel K2,
Guo A4,
Balzer T4,
Gaziano
J1 |
|
|
1VA
Boston
Healthcare
System,
Harvard
Medical
School,
Boston,
MA, USA,
2VA
Boston
Healthcare
System,
Boston,
MA, USA,
3University
of
Southern
California,
Los
Angeles,
CA, USA,
4Berlex
Laboratories,
Wayne,
NJ, USA
|
|
PCV2
|
CARDIOVASCULAR
RISK
FACTORS
IN ACUTE
CORONARY
SYNDROME
PATIENTS
UNDERGOING
PERCUTANEOUS
CORONARY
INTERVENTION
IN 5
EUROPEAN
COUNTRIES
|
|
|
McCollam
PL1,
Nasuti P2,
Bae JP1,
Smith H2 |
|
|
1Eli
Lilly
and
Company,
Indianapolis,
IN, USA,
2IMS
Hospital
Group
Ltd,
Sittingbourne,
UK
|
|
PCV3
|
DO WE
FOLLOW
THE
GUIDELINES
ON
PREVENTION
OF
CARDIOVASCULAR
DISEASE
IN
OUT-PATIENT
CARE ?
|
|
|
Pietrasik
A1,
Starczewska
M1,
Glowczynska
R1,
Opolski
G1,
Filipiak
KJ1,
Jakubczyk
M2,
Niewada
M1,
Latek M3 |
|
|
1Medical
University
of
Warsaw,
Warsaw,
Poland,
2Warsaw
School
of
Economics,
Warsaw,
Poland,
3Warsaw
School
of
Economics,
Warszawa,
Poland
|
|
PCV4
|
META-ANALYSIS
OF THE
DIAGNOSTIC
ACCURACY
OF
PRESSURE
MEASUREMENTS
IN
CORONARY
ARTERY
DISEASE
|
|
|
Bornschein
B1,
Klauss V2,
Siebert
U1 |
|
|
1UMIT
University
of
Health
Sciences,
Medical
Informatics,
and
Technology,
Hall i.
T,
Austria,
2University
of
Munich,
Munich,
Germany
|
|
PCV5
|
DRUG-ELUTING STENT USE IS ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS
IN LONG-TERM CLINICAL OUTCOMES
|
|
|
Eisenstein
EL,
Tuttle
RH, Shaw
LK,
Anstrom
KJ, Kong
DF |
|
|
Duke
Clinical
Research
Institute,
Durham,
NC, USA
|
|
PCV6
|
REACHING
SIGN
CHOLESTEROL
TARGETS
AND
BEYOND:
RETROSPECTIVE
AUDIT OF
TARGETS
ACHIEVED
THROUGH
USE OF
ROSUVASTATIN
IN A
SCOTTISH
GENERAL
PRACTICE
|
|
|
Burnett
GR1,
Dickson
K1,
Emmas CE2 |
|
|
1Princes
Street
Surgery,
Thurso,
Scotland,
UK,
2AstraZeneca
UK,
Luton,
UK
|
|
PCV7
|
REACHING
AWMSG
TARGETS
AND
BEYOND-A
RETROSPECTIVE
AUDIT OF
TARGETS
ACHIEVED
THROUGH
USE OF
ROSUVASTATIN
IN WELSH
GENERAL
PRACTICE
|
|
|
Moore RP1,
Chapman
JR1,
Davies
EJ1,
Davies
SH1,
Davies N1,
Harfoot
DA1,
Emmas CE2 |
|
|
1Towers
Surgery,
Barry,
Wales,
UK,
2AstraZeneca
UK,
Luton,
UK
|
|
PCV8
|
THE
EFFECTIVENESS
OF
ROSUVASTATIN
COMPARED
WITH
OTHER
STATINS
–
RESULTS
FROM A
ROUTINE
CLINICAL
PRACTICE
SETTING
IN THE
UK
|
|
|
Hirsch
MW1, O'Donnell JC1, Jansen JP2 |
|
|
1AstraZeneca
Ltd,
Macclesfield,
Cheshire,
UK,
2Mapi
Values,
Houten,
The
Netherlands
|
|
PCV9
|
NON-PERSISTENT
USE OF
ANTIHYPERTENSIVE
DRUGS
LEADS TO
INCREASED
RISK OF
HOSPITALIZATIONS
FOR
ACUTE
MYOCARDIAL
INFARCTION
OR
STROKE
|
|
|
Breekveldt-Postma
NS1,
Siiskonen
SJ1,
Penning-van
Beest FJ1,
Falvey H2,
Vincze G2,
Erkens
JA1,
Herings
RM1 |
|
|
1PHARMO
Institute
for Drug
Outcomes
Research,
Utrecht,
The
Netherlands,
2Novartis
Pharma
AG,
Basel,
Switzerland
|
|
PCV10
|
COST-EFFECTIVENESS
OF A
LIFESTYLE
INTERVENTION
FOR
HYPERTENSION:
AN OPEN
RANDOMISED
CONTROLLED
TRIAL
|
|
|
Martikainen
JA1,
Kastarinen
M2,
Puska P3,
Nissinen
A3 |
|
|
1Centre
for
Pharmaceutical
Policy
and
Economics
(CEPPE),
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
2Kuopio
University
Hospital,
PL 1777,
Kuopio,
Finland,
3National
Public
Health
Institute,
00300,
Helsinki,
Finland
|
|
PCV11
|
CLINICAL
EFFECTIVENESS
OF
BETALOC
ZOC
COMPARED
TO
METOPROLOL
TARTRATE
OR
CARVEDILOL
IN
HYPERTENSION
TREATMENT.
|
|
|
Kawalec
P1, Borek E2 |
|
|
1Jagiellonian
University,
Kraków,
Poland,
2Astra
Zeneca
Poland,
Warsaw,
Poland
|
|
PCV12
|
Withdrawn |
|
|
|
|
 |
|
PCV13
|
EFFECT
OF
ABSOLUTE
REDUCTION
IN LDL
CHOLESTEROL
ON
CARDIOVASCULAR
EVENTS:
DOES
FINAL
LDL
CHOLESTEROL
ACHEIVED
MATTER?
|
|
|
Rahilly
CR1,
Gaziano
J2,
Scranton
R2 |
|
|
1Boston
VA
Healthcare
System,
Jamaica
Plain,
MA, USA,
2VA
Boston
Healthcare
System,
Harvard
Medical
School,
Boston,
MA, USA
|
|
PCV14
|
ASCOT-LIKE
PATIENT
PREVALENCE
AMONG
THE
HYPERTENSIVES
IN SPAIN
|
|
|
Sicras A1,
F
Bobadilla
J2,
Moreno R3,
Arístegui
R2,
García M4 |
|
|
1Badalona
Servicios
Asistenciales,
Barcelona,
Spain,
2Pfizer
Spain,
Alcobendas,
Madrid,
Spain,
3Hospital
Clinico
San
Carlos,
Madrid,
Madrid,
Spain,
4Euroclin
Institute,
Alcobendas,
Madrid,
Spain
|
|
PCV15
|
ANALYSIS
OF
PRESCRIBING
PATTERNS
OF
ANTIHYPERTENSIVE
AGENTS
(AA)
BEFORE
AND
AFTER
PUBLICATION
OF THE
ANTIHYPERTENSIVE
AND
LIPID-LOWERING
TREATMENT
TO
PREVENT
HEART
ATTACK
TRIAL
(ALLHAT)
|
|
|
Brixner
D1, Maio V2 |
|
|
1The
University
of Utah
College
of
Pharmacy,
Salt
Lake
City,
UT, USA,
2Thomas
Jefferson
University,
Philadelphia,
PA, USA
|
|
PCV16
|
MAIN
CARDIOVASCULAR
RISK
FACTORS:
ASSOCIATION
AND
CONTROL
IN A
PRIMARY
HEALTHCARE
SETTING
|
|
|
Sicras A1,
Navarro
R1,
Rejas J2,
F
Bobadilla
J2,
García M3,
González
P2 |
|
|
1Badalona
Servicios
Asistenciales,
Badalona,
Barcelona,
Spain,
2Pfizer
Spain,
Alcobendas,
Madrid,
Spain,
3Euroclin
Institute,
Alcobendas,
Madrid,
Spain
|
|
PCV17
|
PROJECTED
IMPACT
ON
CORONARY
HEART
DISEASE
OF
ADDING
PROLONGED-RELEASE
NICOTINIC
ACID
(NIASPAN®)
TO
STATIN
TREATMENT
IN
EUROPEAN
PATIENTS
WITH
TYPE 2
DIABETES
|
|
|
Liens D1, Palmer AJ2, Valentine WJ2,
Renaudin
C1,
Roze S2 |
|
|
1Merck
Santé,
Lyon,
France,
2CORE
- Center
for
Outcomes
Research,
A Unit
of IMS,
Allschwil,
Switzerland
|
|
PCV18
|
OUTCOME
OF
THIAZOLIDINEDIONE
USE IN
DISCHARGED
DIABETIC
PATIENTS
WHO WERE
HOSPITALIZED
FOR
HEART
FAILURE
|
|
|
Chou HY1, Huang WF2, Tsai YW3 |
|
|
1National
Yang-Ming
University,
Taipei
City,
Taiwan,
2National
Yang-Ming
University,
Taipei,
Taiwan,
3National
Health
Research
Institutes,
Zhunan
Town,
Miaoli
County,
Taiwan
|
|
PCV19
|
DISCONTINUED
USE OF
MYCOPHENOLATE
MOFETIL
AND
GRAFT
LOSS IN
HEART
TRANSPLANT
RECIPIENTS
|
|
|
Legorreta
AP1, Kang N2 ,
Gilmore
AS2,
Marehbian
J2,
Naujoks C3 , Machnicki G3 |
|
|
1UCLA
School
of
Public
Health,
Los
Angeles,
CA, USA,
2Health
Benchmarks,
Inc,
Woodland
Hills,
CA, USA, 3Novartis Pharma AG, Basel, Switzerland
|
|
 |
|
Cost
Studies |
|
PCV20
|
FINANCIAL
IMPACT
OF
EPLERENONE
USE IN A
SPANISH
REFERENCE
HOSPITAL
|
|
|
F
Bobadilla
J1,
García M2 |
|
|
1Pfizer
Spain,
Alcobendas,
Madrid,
Spain,
2Euroclin
Institute,
Alcobendas,
Madrid,
Spain
|
|
PCV21
|
ANTIHYPERTENSIVE
DRUG
BUDGET
IMPACT
OF THE
ANGIOTENSIN
II
RECEPTOR
BLOCKERS
(ARB) IN
THE UK
|
|
|
Blak BT1, Weir MR1, Simoni-Wastila L1, Shaya
FT1,
Cooke CE2,
Mullins
CD1 |
|
|
1University
of
Maryland,
Baltimore,
MD, USA,
2Pfizer
Inc,
Ellicott
City,
MD, USA
|
|
PCV22
|
COST
IMPACT
OF
DIAGNOSTIC
IMAGING
FOR
LOWER
EXTREMITY
PERIPHERAL
VASCULAR
DISEASE
(PVD)
|
|
|
Hay JW1, Scranton R2, Yucel K3, Guo A4,
Balzer T4,
Gaziano
J2 |
|
|
1University
of
Southern
California,
Los
Angeles,
CA, USA,
2VA
Boston
Healthcare
System,
Harvard
Medical
School,
Boston,
MA, USA,
3VA
Boston
Healthcare
System,
Boston,
MA, USA,
4Berlex
Laboratories,
Wayne,
NJ, USA
|
|
PCV23
|
ECONOMIC
BURDEN
OF
CONTRAST-INDUCED
NEPHROPATHY
(CIN):
IMPLICATIONS
FOR
PREVENTION
STRATEGIES
|
|
|
Subramanian
S1,
Bapat B2,
Zyczynski
T3,
Tumlin J4 |
|
|
1RTI
International,
Waltham,
MA, USA,
2RTI
Interntional,
Research
Triangle
Park,
NC, USA,
3GE
Healthcare,
Princeton,
NJ, USA,
4University
of NC
and
Southeast
Renal
Associates,
Charlotte,
NC, USA
|
|
PCV24
|
CARDIOVASCULAR
EVENTS
REDUCTION
AND
COST-EFFECTIVENESS
OF
ATORVASTATIN
VERSUS
PRAVASTATIN
IN
SPANISH
POPULATION
WITH
ACUTE
CORONARY
SYNDROME
(ACS)
|
|
|
F
Bobadilla
J1,
Checa JC1,
Soto J1,
García M2,
Martínez
E1,
Hernández
G1 |
|
|
1Pfizer
Spain,
Alcobendas,
Madrid,
Spain,
2Euroclin
Institute,
Alcobendas,
Madrid,
Spain
|
|
PCV25
|
COST-EFFECTIVENESS
OF
CLOPIDOGREL
IN
MEXICO:
WITHIN
TRIAL
ANALYSIS
|
|
|
Jerjes-Sanchez
C1,
Trujillo
A2,
Ramos MA3,
Hernandez
I4,
Alvarado
R5,
Cruz A6,
Rangel
FJ6,
Morales
E7 |
|
|
1Hospital
de
Enfermedades
Cardiovasculares
y
Torax-IMSS,
Monterrey,
Nuevo
León,
Mexico,
2Hospital
General
de Zona
57,
Tlalnepantla,
Mexico,
Mexico,
3UMAE
CM La
Raza,
Mexico
City,
Mexico
City,
Mexico,
4Hospital
Juarez
de
Mexico,
Mexico
City,
Mexico,
Mexico,
5ISSSTE
Durango,
Durango,
Durango,
Mexico,
6Hospital
PEMEX-Norte,
Mexico
City,
Mexico
City,
Mexico,
7Cardiometabolic
Research
Unit,
Aguascalientes,
Aguascalientes,
Mexico
|
|
PCV26
|
COST-EFFECTIVENESS
OF
CLOPIDOGREL
IN
MEXICO:
A LONG
TERM
ANALYSIS
|
|
|
Jerjes-Sanchez
C1,
Trujillo
A2,
Ramos MA3,
Hernandez
I4,
Alvarado
R5,
Cruz A6,
Rangel
FJ6,
Morales
E7 |
|
|
1Hospital
de
Enfermedades
Cardiovasculares
y
Torax-IMSS,
Monterrey,
Nuevo
León,
Mexico,
2Hospital
General
de Zona
57,
Tlalnepantla,
Mexico,
Mexico,
3UMAE
CM La
Raza,
Mexico
City,
Mexico,
4Hospital
Juarez
de
Mexico,
Mexico
City,
Mexico,
5ISSSTE
Durango,
Durango,
Mexico,
6Hospital
PEMEX-Norte,
Mexico
City,
Mexico,
7Cardiometabolic
Research
Unit,
Aguascalientes,
Mexico
|
|
PCV27
|
COST-EFFECTIVENESS
OF
BETALOC
COMPARED
TO
CARVEDILOL
IN
CARDIAC
INSUFFICIENCY
AND
ARTERIAL
HYPERTENSION
TREATMENT
IN
POLAND
|
|
|
Kawalec
P1, Borek E2 |
|
|
1Jagiellonian
University,
Kraków,
Poland,
2Astra
Zeneca
Poland,
Warsaw,
Poland
|
|
PCV28
|
COST-EFFECTIVENESS
OF
INTENSIVE
LIPID-LOWERING
TREATMENT
IN
SECONDARY
CARDIOVASCULAR
PREVENTION
IN SPAIN
AND
GERMANY
|
|
|
Taylor DC1, Pandya
A1,
Thompson
D1,
Chu P1,
Graff J2,
LaRosa
JC3,
Grundy
SM4,
Wenger
NK5,
Shepherd
J6,
Drummond
MF7 |
|
|
1i3
Innovus,
Medford,
MA, USA,
2Pfizer,
Inc, New
York,
NY, USA,
3State
University
of New
York
Health
Science
Center,
Brooklyn,
NY, USA,
4University
of
Texas,
Dallas,
TX, USA,
5Emory
University
School
of
Medicine,
Atlanta,
GA, USA,
6University
of
Glasgow,
Glasgow,
Scotland,
UK,
7University
of York,
York,
Heslington,
UK
|
|
PCV29
|
COST-EFFECTIVENESS
ANALYSIS
OF
ROSUVASTATIN
IN
TREATING
PATIENTS
TO LDL-C
ATP III
GOALS. A
MEXICAN
PERSPECTIVE
OF THE
STELLAR
TRIAL.
|
|
|
Soto H1, Mino D2, Polanco AC1, Gomez G3,
Miller P4 |
|
|
1Astra
Zeneca,
Naucalpan,
Estado
de
México,
Mexico,
2Instituto
Mexicano
de
Seguro
Social,
México
D.F,
México,
Mexico,
3Hospital
General
Dr.
Manuel
Gea
Gonzalez,
México
D.F,
México
D.F,
Mexico,
4Astra
Zeneca,
Alderley
Park,
Alderley
Park, UK
|
|
PCV30
|
COST-EFFECTIVENESS
OF
ROSUVASTATIN
FOR
CARDIOVASCULAR
PREVENTION
IN
HIGH-RISK
POPULATIONS
IN
SWEDEN
|
|
|
Jönsson
L1,
Ekman M2,
Karlsson
G3,
Brun J3 |
|
|
1European
Health
Economics,
London,
UK,
2Stockholm
Health
Economics,
Stockholm,
Sweden,
3AstraZeneca,
Södertälje,
Sweden
|
|
PCV31
|
HEALTH
ECONOMIC
ASSESSMENT
OF
RAISING
HDL-C
WITH
PROLONGED-RELEASE
NICOTINIC
ACID
(NIASPAN®)
WHEN
ADDED TO
STATIN
THERAPY
IN
PATIENTS
WITH
DYSLIPIDEMIA
AND TYPE
2
DIABETES:
AN
ANALYSIS
FOR
SWEDEN
|
|
|
Renaudin
C1,
Liens D1,
Palmer
AJ2,
Valentine
WJ2,
Berger W3,
Roze S2 |
|
|
1Merck
Santé,
Lyon,
France,
2CORE
- Center
for
Outcomes
Research,
A Unit
of IMS,
Allschwil,
Switzerland,
3Merck
KGaA,
Darmstadt,
Germany
|
|
PCV32
|
COST-EFFECTIVENESS
OF
CLOPIDOGREL
IN
MYOCARDIAL
INFARCTION
WITH
ST-SEGMENT
ELEVATION:
EUROPEAN
MODEL
RESULTS
BASED ON
CLARITY
AND
COMMIT
|
|
|
Berg J1, Lindgren P1, Jönsson B2 |
|
|
1Stockholm
Health
Economics,
Stockholm,
Sweden,
2Stockholm
School
of
Economics,
Stockholm,
Sweden
|
|
PCV33
|
COST-EFFECTIVENESS
MODEL TO
EVALUATE
MANAGED
VENTRICULAR
PACING
(MVP)
IMPLANTED
IN A
SPANISH
AMBULATORY
SURGERY
PROGRAM
|
|
|
Rodríguez
J1,
Caro JJ2,
Roda J3,
Ward A2,
Xenakis
J2,
Malik F4,
Bariz H2 |
|
|
1Medtronic
Iberia,
Madrid,
Spain,
2Caro
Research
Institute,
Concord,
MA, USA,
3General
Valencia
University
Hospital,
Valencia,
Spain,
4Medtronic
Sarl,
Tolochenaz,
Laussane,
Switzerland
|
|
 |
|
PCV34
|
A
COST-EFFECTIVENESS
ANALYSIS
OF
OLMESARTAN
IN THE
TREATMENT
OF
ARTERIAL
HYPERTENSION
|
|
|
Lamotte
M1, Annemans L2, Van Loy R3, Koch W4 |
|
|
1IMS
Health,
Brussel,
Brabant,
Belgium,
2IMS
Health,
Brussels,
Belgium,
3Sankyo
Pharma,
Louvain-La-Neuve,
Brabant,
Belgium,
4HaaPACS
GmbH,
Schriesheim,
Schriesheim,
Germany
|
|
PCV35
|
ESTIMATING
LIFETIME
COSTS
AND LIFE
EXPECTANCY
ASSOCIATED
WITH
CARDIOVASCULAR
DISEASE
IN A
SWISS
POPULATION
WITH AND
WITHOUT
METABOLIC
SYNDROME
|
|
|
Ray J1, Darioli R2, Roze S3, Azoulay M4,
Bernhardt
M4,
Valentine
WJ5 |
|
|
1IMS
Health,
Allschwil,
Basel,
Switzerland,
2Centre
Hospitalier
Universitaire
Vaudois,
Lausanne,
Switzerland,
3CORE
- Center
for
Outcomes
Research,
A Unit
of IMS,
Allschwil,
Switzerland,
4sanofi-aventis
(suisse)
sa,
Meyrin,
Geneva,
Switzerland,
5CORE
- Center
for
Outcomes
Research,
A Unit
of IMS,
Allschwil,
Basel,
Switzerland
|
|
PCV36
|
A HEALTH
ECONOMIC
EVALUATION
OF
CONCOMITANT
SURGICAL
ABLATION
FOR
ATRIAL
FIBRILLATION
|
|
|
Lamotte
M1, Annemans L2, Siebert M3 |
|
|
1IMS
Health,
Brussel,
Brabant,
Belgium,
2IMS
Health,
Brussels,
Belgium,
3St-Jude
Medical,
Zaventem,
Vlaams
Brabant,
Belgium
|
|
PCV37
|
COST-EFFECTIVENESS
OF
LONG-TERM
TREATMENT
OF
HYPERTENSION
WITH
IRBESARTAN
VS.
LOSARTAN
OR NO
TREATMENT
IN
DENMARK
|
|
|
Knudsen
MS1,
Lange M2,
Dahl E3 |
|
|
1Muusmann
Research
&
Consulting
AS,
Copenhagen,
Denmark,
2Sanofi-aventis,
Hoersholm,
Denmark,
3Bristol-Myers
Squibb,
Lyngby,
Denmark
|
|
PCV38
|
COST
MINIMIZATION
ANALYSIS
OF
BIVALIRUDIN
VERSUS
HEPARIN
PLUS
PLANNED
ABXICIMAB
IN
PATIENTS
UNDERGOING
PERCUTANEOUS
CORONARY
INTERVENTION
|
|
|
Cequier
Á1,
Morís C2,
Badia X3,
Lara N3 |
|
|
1Hospital
Universitario
de
Bellvitge.
Universidad
de
Barcelona,
Barcelona,
Barcelona,
Spain,
2Hospital
Universitario
Central
de
Asturias,
Asturias,
Asturias,
Spain,
3Health
Outcomes
Research
Europe,
Barcelona,
Spain
|
|
PCV39
|
PHARMACOLOGICAL
TREATMENT
OF
HYPERTENSION
IN
PATIENTS
WITH
TYPE II
DIABETES
A
COST-MINIMIZATION
ANALYSIS
|
|
|
Berto P1, Cremonesi G2 |
|
|
1Pbe
consulting,
Verona,
Italy,
2Chiesi
Farmaceutici,
Parma,
Italy
|
|
PCV40
|
A
COST-EFFECTIVENESS
ANALYSIS
OF
CARDIAC
REHABILITATION
AFTER
PERCUTANEOUS
CORONARY
INTERVENTIONS
|
|
|
Lamotte
M1, Annemans L2, Raskin A3, Hansen D3,
Dendale
P3 |
|
|
1IMS
Health,
Brussel,
Brabant,
Belgium,
2IMS
Health,
Brussels,
Belgium,
3Virga
Jesse
Hospital,
Hasselt,
Limburg,
Belgium
|
|
PCV41
|
A COST
CONSEQUENCE
ANALYSIS
OF THE
IMPACT
OF JBS 2
ON
PATIENTS
ELIGIBLE
FOR
STATIN
TREATMENT
IN
SCOTLAND
|
|
|
Shepherd
J1,
Kingslake
SL2 |
|
|
1University
of
Glasgow,
Glasgow,
Scotland,
UK,
2AstraZeneca
UK Ltd,
Luton,
Bedfordshire,
UK
|
|
| | | |